American biotechnology company at South San Francisco in California, founded in 2019, which works on small molecule medicines for targets that have been considered undruggable. Combines chemoproteomics with machine learning on its own platform to find covalent binding sites across the proteome, runs programmes against mutant KRAS and other cancer targets, and has worked with larger pharmaceutical partners on discovery collaborations.
コメントはありません。
評価とコメントを残す